Capreomycini sulfas: Capreomycin sulfate.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 312
- Publication type:
- Article
Works matching IS 10109609 AND DT 2010 AND VI 24 AND IP 4
Results: 40
1
2
Evaluation of future nanomedicines.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 311
- Publication type:
- Article
3
Tocilizumab: risk of fatal anaphylaxis.
- Published in:
- 2010
- Publication type:
- Journal Article
4
Levofloxacin tablets.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 342
- Publication type:
- Article
5
Levofloxacin.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 337
- Publication type:
- Article
6
Levamisole tablets.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 334
- Publication type:
- Article
7
International Nonproprietary Names for Pharmaceutical Substances (INN).
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 351
- Publication type:
- Article
8
Levonorgestrel tablets.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 346
- Publication type:
- Article
9
Emtricitabini ettenofoviri compressi: Emtricitabine and tenofovir tablets.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 330
- Publication type:
- Article
10
Efavirenz tablets.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 319
- Publication type:
- Article
11
Capreomycini add injectionem: Capreomycin for injection.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 316
- Publication type:
- Article
12
Reporting on opioid inaccessibility.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 311
- Publication type:
- Article
13
Emtricitabinum capsulae: Emtricitabine capsules.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 327
- Publication type:
- Article
14
Efavirenz, emtricitabine and tenofovir tablets.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 323
- Publication type:
- Article
15
Clinical trials and global medicines development.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 310
- Publication type:
- Article
16
US Government to share patents with Medicines Patent Pool.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 310
- Publication type:
- Article
17
EMA and US FDA extend confidentiality arrangements indefinitely.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 309
- Publication type:
- Article
18
Mometasone furoate/ formoterol fuma rate: withdrawal of marketing authorization application.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 309
- Publication type:
- Article
19
Aliskiren/valsartan: withdrawal of marketing authorization application.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 308
- Publication type:
- Article
20
Testosterone transdermal patch: withdrawal of extension of indication application.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 308
- Publication type:
- Article
21
Sibutramine-containing medicines: withdrawal.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 308
- Publication type:
- Article
22
Sibutramine: suspension of sales.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 307
- Publication type:
- Article
23
Sitaxentan: worldwide withdrawal.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 307
- Publication type:
- Article
24
Propoxyphene: recommendation against use.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 306
- Publication type:
- Article
25
Human normal immunoglobulin: suspension of marketing authorization.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 306
- Publication type:
- Article
26
Statins: interstitial lung disease.
- Published in:
- 2010
- Publication type:
- Excerpt
27
Gadolinium-based contrast agents: kidney dysfunction.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 302
- Publication type:
- Article
28
Modified-release oral opioids: suspension of marketing authorization.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 306
- Publication type:
- Article
29
Rosiglitazone-containing antidiabetes medicines: suspension of marketing authorization.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 305
- Publication type:
- Article
30
Tamoxifen: drug interactions involving CYP2D6 genetic variants.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 303
- Publication type:
- Article
31
Pioglitazone: potential bladder cancer.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 301
- Publication type:
- Article
32
Zoledronic acid solution: renal dysfunction.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 304
- Publication type:
- Article
33
Influenza vaccines: 2011 southern hemisphere.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 305
- Publication type:
- Article
34
GnRH agonists, diabetes and cardiovascular disease.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 301
- Publication type:
- Article
35
Angiotensin receptor blockers and cancer: safety review.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 301
- Publication type:
- Article
36
Tinzaparin sodium: renal impairment in elderly.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 303
- Publication type:
- Article
37
Lamotrigine: aseptic meningitis.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 302
- Publication type:
- Article
38
H1N1 influenza vaccine: narcolepsy.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 299
- Publication type:
- Article
39
WHO initiates pilot prequalification of active pharmaceutical ingredients.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 297
- Publication type:
- Article
40
WHO Prequalification of medicines Programme: survey of service quality provided to manufacturers.
- Published in:
- WHO Drug Information, 2010, v. 24, n. 4, p. 293
- Publication type:
- Article